Failure of tofacitinib to achieve an objective response in a


Journal

Cold Spring Harbor molecular case studies
ISSN: 2373-2873
Titre abrégé: Cold Spring Harb Mol Case Stud
Pays: United States
ID NLM: 101660017

Informations de publication

Date de publication:
08 2020
Historique:
received: 19 11 2019
accepted: 05 06 2020
entrez: 27 8 2020
pubmed: 28 8 2020
medline: 7 7 2021
Statut: epublish

Résumé

T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia (T-LBL/T ALL) is an aggressive hematological malignancy arising from malignant transformation of T-cell progenitors with poor prognosis in adult patients. Outcomes are particularly dismal in the relapsed/refractory setting, and therapeutic options are limited in this context. Genomic profiling has shown frequent aberrations in the JAK-STAT pathway, including recurrent mutations in

Identifiants

pubmed: 32843425
pii: mcs.a004994
doi: 10.1101/mcs.a004994
pmc: PMC7476415
pii:
doi:

Substances chimiques

MLLT10 protein, human 0
Piperidines 0
Pyrimidines 0
Transcription Factors 0
tofacitinib 87LA6FU830
JAK1 protein, human EC 2.7.10.2
JAK3 protein, human EC 2.7.10.2
Janus Kinase 1 EC 2.7.10.2
Janus Kinase 3 EC 2.7.10.2
DDX3X protein, human EC 3.6.1.-
DEAD-box RNA Helicases EC 3.6.4.13

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020 Wong et al.; Published by Cold Spring Harbor Laboratory Press.

Références

Blood. 2014 Nov 13;124(20):3092-100
pubmed: 25193870
PLoS One. 2012;7(6):e38463
pubmed: 22675565
Blood. 2017 Mar 2;129(9):1113-1123
pubmed: 28115373
J Hematol Oncol. 2015 Jul 26;8:91
pubmed: 26208852
J Clin Oncol. 2011 Aug 10;29(23):3185-93
pubmed: 21747090
Haematologica. 2015 Oct;100(10):1301-10
pubmed: 26206799
Immunol Rev. 2005 Feb;203:127-42
pubmed: 15661026
Blood. 2013 Jun 20;121(25):5064-7
pubmed: 23673860
Case Rep Hematol. 2018 Aug 26;2018:6092646
pubmed: 30225152
Br J Haematol. 2016 Apr;173(2):265-73
pubmed: 26917488
Leuk Lymphoma. 2019 Jul;60(7):1626-1631
pubmed: 30997845
Blood Adv. 2017 Dec 18;1(27):2724-2728
pubmed: 29296924
Int J Biochem Cell Biol. 2009 Dec;41(12):2376-9
pubmed: 19747563
Oncogene. 2010 Jun 24;29(25):3723-31
pubmed: 20400977
Blood. 2014 Aug 28;124(9):1460-72
pubmed: 24825865
Leukemia. 2018 Mar;32(3):774-787
pubmed: 28804127
Genes Chromosomes Cancer. 2016 Jan;55(1):82-94
pubmed: 26493028
JCO Precis Oncol. 2018;2018:
pubmed: 30079384
Clin Cancer Drugs. 2016;3(2):131-137
pubmed: 29046866
Blood. 2014 Oct 23;124(17):2705-12
pubmed: 25224413
J Clin Invest. 2016 Apr 1;126(4):1267-81
pubmed: 26974155
Leukemia. 2015 Dec;29(12):2427-9
pubmed: 26449659
Genes Chromosomes Cancer. 2014 Apr;53(4):309-16
pubmed: 24446122
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Blood. 2017 Mar 2;129(9):1134-1142
pubmed: 28115371
Leukemia. 2014 Feb;28(2):417-9
pubmed: 24048415
Leukemia. 2012 Sep;26(9):2144-6
pubmed: 22425895
Blood. 2018 Jan 25;131(4):421-425
pubmed: 29187379
Blood. 1994 Nov 1;84(9):3105-12
pubmed: 7949183
Nat Genet. 2013 Feb;45(2):186-90
pubmed: 23263491
J Biol Chem. 2015 Nov 27;290(48):29022-34
pubmed: 26446793
Blood. 2014 Dec 11;124(25):3738-47
pubmed: 25301704
Leuk Lymphoma. 1997 May;25(5-6):579-83
pubmed: 9250830
Bioorg Med Chem Lett. 2014 Oct 1;24(19):4617-4621
pubmed: 25217444
Leuk Lymphoma. 2015 May;56(5):1502-6
pubmed: 25146434
JCO Precis Oncol. 2018;2:
pubmed: 31080940
J Inflamm (Lond). 2010 Aug 11;7:41
pubmed: 20701804
Cancer Discov. 2014 Sep;4(9):1074-87
pubmed: 24994123
J Med Chem. 2010 Dec 23;53(24):8468-84
pubmed: 21105711
Haematologica. 2014 May;99(5):64-6
pubmed: 24584351
Cancer. 2004 Dec 15;101(12):2788-801
pubmed: 15481055
PLoS Genet. 2013;9(12):e1003997
pubmed: 24367274
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106
Curr Opin Hematol. 2014 Jul;21(4):297-308
pubmed: 24811162

Auteurs

Jonathan Wong (J)

Department of Hematology, Monash Health, Clayton, 3168, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, 3168, Victoria, Australia.

Meaghan Wall (M)

School of Clinical Sciences, Monash University, Clayton, 3168, Victoria, Australia.
Victorian Cancer Cytogenetics Service, St Vincent's Hospital, Fitzroy, 3065, Victoria, Australia.
St Vincent's Institute, Fitzroy, 3065, Victoria, Australia.
Monash Pathology, Monash Health, Clayton, 3168, Victoria, Australia.

Gregory Philip Corboy (GP)

Department of Hematology, Monash Health, Clayton, 3168, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, 3168, Victoria, Australia.
Department of Clinical Pathology, The University of Melbourne, Parkville, 3010, Victoria, Australia.

Nadine Taubenheim (N)

Monash Pathology, Monash Health, Clayton, 3168, Victoria, Australia.
Center for Cancer Research, Hudson Institute of Medical Research, Clayton, 3168, Victoria, Australia.

Gareth Peter Gregory (GP)

Department of Hematology, Monash Health, Clayton, 3168, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, 3168, Victoria, Australia.

Stephen Opat (S)

Department of Hematology, Monash Health, Clayton, 3168, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, 3168, Victoria, Australia.

Jake Shortt (J)

Department of Hematology, Monash Health, Clayton, 3168, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, 3168, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH